Ignite Creation Date:
2025-12-25 @ 12:10 AM
Ignite Modification Date:
2025-12-25 @ 10:10 PM
Study NCT ID:
NCT04143958
Status:
WITHDRAWN
Last Update Posted:
2023-04-07
First Post:
2019-10-28
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
Sponsor:
Sanofi
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-09
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-11
Completion Date Type:
ESTIMATED
First Submit Date:
2019-10-28
First Submit QC Date:
None
Study First Post Date:
2019-10-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-04-05
Last Update Post Date:
2023-04-07
Last Update Post Date Type:
ACTUAL